The present application discloses a LED therapeutic device comprising a top case, a light assembly, a controller, a switch assembly, a bottom case and a power supply. The light assembly comprises a lens and a LED assembly, wherein the lens is coupled to the top case and the LED assembly comprises three visible light LEDs and two infrared LEDs. Wavelengths of the three visible light LEDs are 470 nm, 630 nm and 660 nm. Wavelengths of the two infrared LEDs are 850 nm and 940 nm. The controller is coupled to the light assembly. The switch assembly is coupled to the controller. The bottom case is removably coupled to the top case. The power supply is electrically coupled to the controller.

The device includes a laser source (7) adapted to emit a laser radiation at a wavelength between around 620 nm and around 750 nm, and a handpiece (5). The handpiece in turn includes an applicator (11) with a contact surface with the epidermis defining a window (11.1) for the passage of a laser beam (F) toward the epidermis (E) of a subject to be treated. A waveguide (10) conveys the laser radiation from the laser source (7) to a scanning system (17) of the handpiece.

A method and system for of treating type 1 includes implanting genetically modified islet cells under a capsule of or within an organ, implanting a microsystem adjacent the islet cells, said microsystem, comprising a light emitting diode stimulator comprising a plurality of light emitting diodes, determining a glucose level in a body and controlling the microsystem to selectively illuminate the islet cells to secrete insulin or glucagon or both based on the glucose level.

An external auditory canal therapy device may include a housing inserted into an external auditory canal of a human ear, at least one electrically conductive electrode coupled to the housing and one or both of at least one irradiation source and at least one speaker coupled to the housing. An electrical circuit carried by the housing may control the at least one electrically conductive electrode to provide electrically stimulation through the dermis to at least one of an arterial branch and a peripheral nerve branch of at least one cranial nerve, and may control one or both of the at least one irradiation source to irradiate the at least one of the arterial branch and the peripheral nerve branch of the at least one cranial nerve through the dermis and the at least one speaker to produce acoustic waves directed toward a tympanic membrane of the ear.

The present application discloses a LED therapeutic device comprising a top case, a light assembly, a controller, a switch assembly, a bottom case and a power supply. The light assembly comprises a lens and a LED assembly, wherein the lens is coupled to the top case and the LED assembly comprises at least one visible light LED and at least one infrared LED. The controller is coupled to the light assembly. The switch assembly is coupled to the controller. The bottom case is removably coupled to the top case. The power supply is electrically coupled to the controller.

A laser treatment system includes a laser device configured to produce a laser beam at a wavelength in an ultraviolet spectrum to provide for tissue ablation, a lens configured to focus and direct the laser beam to a site to form an opening in a surface of the site, a valve connected to a first channel, and a nozzle that emits the laser beam and controls delivery of at least a first substance and a second substance to the site. A portion of the first channel is disposed within a first sidewall of the nozzle to deliver the first substance, and a second channel unconnected with the valve is disposed within a second sidewall of the nozzle to deliver the second substance.

Dermal neurofibroma, in particular Neurofibromatosis Type I (NF1) leads to progressive tumor proliferation with no known mechanism to inhibit growth. The present invention relates to the use of photodynamic therapy (PDT) for attenuating tumor growth in NF1 patients. More particularly the invention provides a method of treating dermal neurofibroma comprising topically applying a pharmaceutical composition comprising a photosensitizer to the affected area of a patient, incubating the affected area, and irradiating the affected area with a light of suitable wavelength as per the photosensitizer used, wherein the treatment is characterized by inhibiting the progression of tumor growth and/or reduction in tumor size and/or increased mortality rate of the neurofibroma cell.

The cannula can have a connector configured to be electrically connected to a source of electrical power; a tip comprising: a printed circuit board (PCB); a first LED operatively connected and attached to the PCB and configured to emit light in a first wavelength range; and a shell configured to allow the light in the first wavelength range to pass from the first LED outside of the shell; and a middle section located between the connector and the tip, the middle section comprising: a hollow tube attached to the shell, the tube having apertures for collecting a liquid fat into the tube.

The invention provides an IPG and lead configuration which boasts both a novel optical folding assembly and an optical processor assembly which offers the advantages of low heat generation and compact package size. The surgical leads provided offer additional advantages over the prior art including integral formation of optical and electrical components in a compact size. The invention further provides processing advantages which measure and compensate for degradation in the optical system over time.

The invention provides an EPG system and lead configuration which boasts both a novel optical folding assembly and compact package size. The percutaneous leads provided offer additional advantages over the prior art including integral formation of optical and electrical components in a compact size.